Fresenius Medical Care AG & Co. KGaA (FMS) Research

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Market snapshot

Symbol
FMS
Price
$23.59
Day change
+0.08%
Market cap
$10.9B
P/E ratio
11.84x
52-week range
20.02-28.87
Sector
Healthcare
Industry
Medical - Care Facilities
Next earnings
in 2 months
Analyst price target
$28.00

Recent news

  • Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

    The dialysis specialist started restructuring its U.S. network by exiting 64 of up to 100 clinics.

  • Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

    Fresenius Medical Care said ​on Tuesday its ‌revenue fell 6% in the first ​quarter of ​2026, weighed down by ⁠significant currency ​effects, mainly from ​the weak U.S. dollar, and recent divestitures.

Peer companies

  • DaVita Inc. (DVA)
  • Encompass Health Corporation (EHC)
  • Hologic, Inc. (HOLX)
  • ICON Public Limited Company (ICLR)
  • Royalty Pharma plc (RPRX)
  • Smith & Nephew plc (SNN)
  • Solventum Corporation (SOLV)
  • Tempus AI, Inc. (TEM)

Recent insider activity

  • Renkewitsch Olga — trade (0 shares) on 2026-03-18

Open Fresenius Medical Care AG & Co. KGaA (FMS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.